DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Glioblastoma Multiforme market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Glioblastoma Multiforme market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioblastoma Multiforme Market Insights
Glioblastoma Multiforme Overview
Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Glioblastoma Multiforme is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system.
Some of the key facts of the Glioblastoma Multiforme Market Report:
- The Glioblastoma Multiforme market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The National Cancer Institute estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that 15,320 of these diagnoses resulted in death
- In June 2022, Novartis announced that the US FDA has granted accelerated approval to TAFINLAR (dabrafenib) + MEKINIST (trametinib) for the treatment of advanced tumors that have a mutation called “BRAF V600E.”
- According to the American Association of Neurological Surgeons, GBM has an incidence of 2–3 per 100,000 adults per year, and accounts for 52% of all primary brain tumors. Overall, GBM accounts for about 17% of all tumors of the brain (primary and metastatic)
- The total incident population of Glioblastoma Multiforme in the 7MM was 32,546 in 2021. In case of GBM patients in the United States, the incident cases were 13,251 in 2021
- Key Glioblastoma Multiforme Companies: Northwest Therapeutics, Bayer, AstraZeneca, DNAtrix, Chimerix, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, and others
- Key Glioblastoma Multiforme Therapies: DCVax-L, Regorafenib, Durvalumab, DNX-2401, ONC201, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
- The Glioblastoma Multiforme epidemiology based on gender analyzed that Glioblastoma Multiforme is more prevalent among males than females
Get a Free sample for the Glioblastoma Multiforme Market Report –
https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market
Key benefits of the Glioblastoma Multiforme Market report:
- Glioblastoma Multiforme market report covers a descriptive overview and comprehensive insight of the Glioblastoma Multiforme Epidemiology and Glioblastoma Multiforme market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Glioblastoma Multiforme market report provides insights on the current and emerging therapies.
- Glioblastoma Multiforme market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Glioblastoma Multiforme market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Glioblastoma Multiforme market.
Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Epidemiological Insights
Glioblastoma Multiforme Market
The dynamics of the Glioblastoma Multiforme market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Glioblastoma Multiforme Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Glioblastoma Multiforme Epidemiology Segmentation:
The Glioblastoma Multiforme market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Glioblastoma Multiforme
- Prevalent Cases of Glioblastoma Multiforme by severity
- Gender-specific Prevalence of Glioblastoma Multiforme
- Diagnosed Cases of Episodic and Chronic Glioblastoma Multiforme
Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme market or expected to get launched during the study period. The analysis covers Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glioblastoma Multiforme Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Glioblastoma Multiforme market share @ Glioblastoma Multiforme market forecast
Glioblastoma Multiforme Therapies and Key Companies
- DCVax-L: Northwest Therapeutics
- Regorafenib: Bayer
- Durvalumab: AstraZeneca
- DNX-2401: DNAtrix
- ONC201: Chimerix
- Paxalisib(GDC-0084): Kazia Therapeutics
- AV-GBM-1: Aivita Biomedical
- MDNA55: Medicenna Therapeutics
- VAL-083: Kintara Therapeutics
Glioblastoma Multiforme Market Strengths
- Vaccine approaches are an attractive adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are some of the key players developing therapeutic vaccines for Glioblastoma Multiforme
- Owing to the launch of bevacizumab biosimilars, a reduction in cost burden can be witnessed
Scope of the Glioblastoma Multiforme Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Glioblastoma Multiforme Companies: Northwest Therapeutics, Bayer, AstraZeneca, DNAtrix, Chimerix, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, and others
- Key Glioblastoma Multiforme Therapies: DCVax-L, Regorafenib, Durvalumab, DNX-2401, ONC201, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
- Glioblastoma Multiforme Therapeutic Assessment: Glioblastoma Multiforme current marketed and Glioblastoma Multiforme emerging therapies
- Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme market drivers and Glioblastoma Multiforme market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Glioblastoma Multiforme Unmet Needs, KOL’s views, Analyst’s views, Glioblastoma Multiforme Market Access and Reimbursement
Glioblastoma Multiforme Market Opportunities
- Numerous failed clinical trials suggest combination therapies will likely be the most promising method of Glioblastoma Multiforme treatment, and emphasis should be applied to drug design and pharmacokinetic properties
- Better prognostic markers would allow physicians to diagnose and begin treatment of GBM at early onset, possibly preventing disease progression
Table of Contents
1. Glioblastoma Multiforme Market Report Introduction
2. Executive Summary for Glioblastoma Multiforme
3. SWOT analysis of Glioblastoma Multiforme
4. Glioblastoma Multiforme Patient Share (%) Overview at a Glance
5. Glioblastoma Multiforme Market Overview at a Glance
6. Glioblastoma Multiforme Disease Background and Overview
7. Glioblastoma Multiforme Epidemiology and Patient Population
8. Country-Specific Patient Population of Glioblastoma Multiforme
9. Glioblastoma Multiforme Current Treatment and Medical Practices
10. Glioblastoma Multiforme Unmet Needs
11. Glioblastoma Multiforme Emerging Therapies
12. Glioblastoma Multiforme Market Outlook
13. Country-Wise Glioblastoma Multiforme Market Analysis (2019–2032)
14. Glioblastoma Multiforme Market Access and Reimbursement of Therapies
15. Glioblastoma Multiforme Market Drivers
16. Glioblastoma Multiforme Market Barriers
17. Glioblastoma Multiforme Appendix
18. Glioblastoma Multiforme Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Glioblastoma Multiforme treatment, visit @ Glioblastoma Multiforme Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting